ArticleInvestigational new drugs2020

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.

Anthony Wood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.